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antipsychotics in patients with a first episode of psychosis and highlight markedly different patterns of response in the positive, disorganized and negative dimensions. DUP, cannabis use and diagnosis appeared to have a prognostic value in predicting treatment response with different implications for each dimension.
Introduction 3
Patients with schizophrenia are expected to exhibit reduced symptoms after an adequate 4 antipsychotic treatment of 3 to 6 weeks. However, even during the first episode of psychosis, 5 only 55 to 60% of patients will show a significant reduction in the severity of psychotic 6 symptoms during the acute phase of the illness (Lieberman et al., 2003; Crespo-Facorro et al., 7 2006 ). Current research in antipsychotic treatment response usually focuses on aggregate data 8 that compare entire groups of patients, usually ignoring interindividual heterogeneity in response 9
to treatment. An examination of heterogeneity may have a prognostic and clinical utility, since it 10 may help to identify groups of responders and non-responders, the key periods of response in 11 antipsychotic treatment and differences in the response profile for different antipsychotic 12 treatments . Recent research has challenged the delayed response hypothesis 13 in antipsychotic treatment, showing that a response may occur from the first week of 14 antipsychotic treatment and that early responses predict subsequent responses (Agid et al., 2003; 15 Leucht et al., 2005) . The estimates of rapid response have been observed to range from one week 16 (Correll et al., 2003) to two months (Emsley et al., 2006) , and suggest a great variation in the 17 magnitude and time of response. 18
Advances in statistical modeling allow examining the existence of different trajectories of 19 symptom severity over time without a priori definitions such as a cut-off in the treatment 20 response (Muthén et al., 2002; Muthén & Muthén , 2007) . Accordingly, several studies have 21 focused on the heterogeneity of response to antipsychotics, analyzing the pattern of these 22 trajectories over time. Levine et al., (2012) reported finding three response trajectories in a post hoc study of the 6 CATIE trial. However, these authors analyzed trajectories of treatment response assessed by 7 PANSS percent reduction rather than symptom severity (PANSS scores), which renders a 8 comparison of their results with prior trajectory analyses difficult. Interestingly, only one study 9
focusing on a naturalistic intervention in previously treated patients has reported a similar pattern 10 of five trajectories of response based on total PANSS scores (Schennach et al., 2012) . Several 11 predictors have been associated with belonging to particular trajectories including gender, age at 12 illness onset, diagnosis, premorbid adjustment, cognitive performance, length of illness, 13 depressive symptoms, social functioning, and early response to treatment, although there are 14 contradictory results. The methodology of trajectory analysis has also been used to identify 15 different courses of schizophrenia in a population -using patient cohorts and the number of 16 hospitalized days as a proxy of deterioration course (Levine et al., 2011) . 17
A number of methodological issues need to be addressed in the research of treatment 18 response trajectories in schizophrenia, since replication and validation of its results may be 19 difficult. More importantly, most studies have focused on trajectories of responses based on the 20 total score of general psychopathological scales, such as the positive and negative syndrome 21 trajectories of PANSS total scale, and three trajectories for the PANSS positive subscale that did 6 not include an "unsustained response" trajectory. Discriminating response on the basis of 7 specific symptom dimensions may be a productive research approach to the study of response 8 trajectories, given that there may be different pathological basis (Harvey et al., 2006) The inclusion of chronic and previously-treated patients may increase response heterogeneity 16 and also limit the probability of response. Studies based on representative first-episode samples 17 like the one used in the current study may help to avoid or reduce these biases. 18
The objectives of the current research were: 1) to identify the number of distinct 19 trajectories that best define antipsychotic response in a representative sample of drug-naïve first-20 episode psychosis patients; 2) to examine whether distinct response trajectory patterns may be 21 identified using different symptom dimensions of schizophrenia; and 3) to search for factors that 22
predict response trajectories. This study is the first to explore the trajectories of the 3 widely 23 accepted schizophrenia dimensions (psychotic-reality distortion, negative and disorganized) by 1 using a sophisticated and very comprehensive scale that combines the Scale for the Assessment 2 of Negative Symptoms (SANS) (Andreasen, 1983a) and the Scale for the Assessment of Positive 3 Symptoms (SAPS) (Andreasen, 1983b). 4
Method 5

Subjects 6
Detailed descriptions of the sample and primary results on short-term efficacy from this 7 naturalistic randomized clinical trial, which compared effectiveness of treatments with 8 risperidone, olanzapine and haloperidol, have been published elsewhere (Pelayo-Teran et al. , 9 2008) . Briefly, the patients were recruited from an epidemiological catchment area in northern 10 Spain, where the annual incidence of psychosis has been estimated to be 1.38/10,000 inhabitants. 11
Inclusion criteria were: 1) age between 15-60 years; 2) experiencing a first episode of psychosis; 12
3) DSM-IV principal diagnosis of schizophrenia, schizophreniform disorder, schizoaffective 13 disorder, brief psychotic disorder or psychosis not otherwise specified; 4) usually living in the 14 catchment area; 5) no prior treatment with antipsychotic medication or, if previously treated, a 15 total life time of adequate antipsychotic treatment of less than 6 weeks; and 6) having current 16 psychotic symptoms of moderate or greater severity, as assessed by one of the five SAPS items. 17
Patients meeting these criteria and their families provided written informed consent to be 18 included in the study, which conformed to international standards for research ethics and was 19 approved by the local institutional review board. 20 were identified, the model allowed estimating the effect of gender, DUP, cannabis use, 1 antipsychotic type, smoking and diagnosis on the probabilities that a patient has the identified 2
trajectories. 3
The optimal number of group trajectories was identified by using the Bayesian 4
Information Criterion (Jones et al., 2001) . Initially, cubic trajectories were used in all groups. 5
Once the optimal number of groups was identified, nonsignificant polynomial orders were 6 removed from the model. Then, the effects of gender, DUP, cannabis use, antipsychotic and 7 diagnosis on the probabilities of belonging to the group trajectories were investigated. A full 8 model was fitted by including all these variables in the model, and then those variables that did 9
not have a significant effect on any of these probabilities were removed from the model. The 10
final model included only those variables that had some significant effects. SAS PROC TRAJ 11 was used for computations (Jones et al., 2001) . The model uses a generalized logit function to 12 represent the effects of the variables. Thus, the effect (regression coefficient) of a variable on the 13 probability of belonging to a particular trajectory group can be interpreted analogously to the 14 way an effect is interpreted in logistic regression, with the understanding that the particular 15 group is compared with only the reference group. 16
Analogous models were built for the disorganized and negative dimensions of SAPS-17 SANS scores. Sixteen patients who had a disorganized dimension equal to 0 were excluded from 18 the analysis of this dimension for 2 reasons: 1) the normal model is a continuous model that does 19 not allow a mixture of discrete and continuous distributions, and 2) it makes no sense to 20 investigate the evolution of symptoms when there are no initial symptoms. For similar reasons, 21 43 subjects who had a negative dimension equal to 0 were excluded from the analysis of this 22 dimension. The censored normal model was also used to identify trajectories of the Brief 23
Psychiatric Rating Scale (BPRS) total score. 1
Results 2
Analysis of trajectories of antipsychotic treatment response: positive dimension 3
According to the final model, the patients were classified into 5 types depending on their 4 change in the positive dimension of SAPS-SANS scores over time after antipsychotic treatment 5
( Table 1 and Panel A in Figure 1 ). Observe that there is a group of subjects who did not respond 6 or responded very poorly to antipsychotic treatment, according to the positive SAPS-SANS 7 scores (Group 5; Figure 1 -A). 8
The first group included patients with a mean baseline positive SAPS-SANS score of 9 5.0, and responded to treatment well, with a mean score close to 0 at the end of the 6 th week of 10 treatment (Group 1 in Figure 1 -A). We call patients following this trajectory "Responders". The 11 second group of patients had a very high mean baseline score, 10.0, but their scores had been 12 dramatically reduced to nearly 0 at the end of the 6 th week (Group 2); we named patients 13 following this trajectory "Dramatic Responders". The third group had an initial mean score of 14 5.8, and a final score of 2.8 (Group 3); and we called these patients "Partial Responders". The 15 fourth group of patients had an initially high mean score, 9.7, but their mean score dropped 16 substantially to 2.6 during the first 6 weeks of treatment (Group 4). Given that these patients 17 exhibited a high degree of response but the severity of symptoms at the end of the 6 th week was 18 similar to that of the Partial Responders they were called "Slow Partial Responders". The fifth 19 group had the highest positive SAPS-SANS scores and did not appear to respond substantially to 20 antipsychotic treatment during the 6-week follow-up, exhibiting a baseline score of 9.9 and a 21 final score of 7.9 (Group 5). Patients on this trajectory were called "Non-Responders" 22
Patients in groups with higher label numbers tended to be more difficult to treat or to 23 have a more severe illness than patients in groups with a lower label number. For instance, 1 patients in the Non-Responders trajectory (Group 5) had a very high baseline positive SAPS-2 SANS score and had a poorer response to antipsychotic treatment than patients in Group 3 3 (Partial Responders). 4
Cannabis use and DUP had significant effects on the probabilities of having particular 5 positive SAPS-SANS response trajectories ( Table 2 ). Antipsychotic type did not have 6 significant effects on the probabilities of belonging to Groups 2 through 5 compared to Group 1 7 (Table 2) . 8
Effect of cannabis use on positive dimension response trajectories 9
When comparing Non Responders versus Responders, cannabis users had significantly 10 higher odds of being Non Responders than non-users (15.9 times higher, p=0.001; e 2.77 =15.9). 11
When comparing Slow Partial Responders with Responders, the odds that a cannabis user was a 12
Slow Partial Responder was significantly higher than the odds for a non-user (7.3 times higher, 13 p<0.001; e 1.99 =7.32). When comparing Partial Responders versus Responders, cannabis users 14 had significantly higher odds of being Partial Responders than non-users (4.4 times higher, 15 p=0.006; e 1.48 =4.4, Table 2 ). 16
Interestingly, Table 2 shows that there was a gradient in the effect of cannabis use on the 17 severity of (and difficulty in treating) the illness. Parameter estimates show that the effect of 18 cannabis use on the probability of belonging to a particular group increased with illness severity 19 and difficulty in treating the patients in the group (1.01 for Group 2 versus Group 1; 1.48 for 20 Group 3; 1.99 for Group 4; and 2.77 for Group 5). 21
Effect of DUP on positive dimension response trajectories 22
When comparing Non-Responder patients versus Responders, higher DUPs were 23 significantly associated with higher odds of being a Non-Responder (p=0.006; Table 2 ). When 1 focusing on these two subpopulations of patients, each additional year of DUP increased 2 significantly the odds of being a Non-Responder by 5.8% [(e 0.056 -1) × 100=5.8]. Analogous 3 conclusions were obtained when comparing Slow Partial Responders with Responders (p=0.02), 4
and Partial Responders with Responders (p=0.01). 5
Gender, smoking and diagnosis did not significantly affect the type of response trajectory 6 after controlling for antipsychotic treatment, cannabis use and duration of untreated psychosis, 7
according to the positive dimension of the SAPS-SANS score. 8
Analysis of trajectories of antipsychotic treatment response: disorganized dimension 9
Three types of trajectories were identified for the disorganized dimension of SAPS-SANS 10 scores. Table 1 and Figure 1 (Panel B) show the trajectories and the proportions of patients 11 exhibiting the trajectories. Group 1 in Figure 1 -B included patients with a mean baseline 12 disorganized SAPS-SANS score of 7.5, and responded to treatment well, with a mean score of 13 0.6 at the end of the 6 th week of treatment; we call patients following this trajectory 14 "Responders". Group 2 had patients with a mean baseline score of 5.0, and their scores 15 dramatically reduced to nearly 0 at the end of the 6 th week; these patients were named "Dramatic 16
Responders". Group 3 had a high initial mean score of 10.7, and a final score of 5.4 ("Partial 17
Responders"). When comparing Dramatic Responders versus Responders, cannabis users had 18 significantly lower odds of being Dramatic Responders than non-users [65.4% lower, p=0.03; 19 (e −1.06 -1)×100=−65.4; Table 2 ]. Antipsychotic treatment, gender, DUP, smoking and diagnosis 20 did not have significant effects on the probabilities of having a particular trajectory after 21 adjusting for cannabis use. 22
Analysis of trajectories of antipsychotic treatment response: negative dimension 23
Five types of trajectories were identified for the negative dimension of SAPS-SANS 1 score ( Table 1 and Panel C in Figure 1 ). Observe that two trajectories were constant or nearly 2 constant (corresponding to Groups 2 and 3). Patients in these two groups were non-reponders 3 and could be differentiated regarding the severity of the symptoms exhibited. Group 2 included 4 patients with a mean initial score of 4.7 and a final score of 4.3 in the negative SANS dimension; 5
we called these patients "Mild Non-Responders". Group 3 comprised patients with mean initial 6 and final scores of 8.1, called "Moderate Non-Responders". The other three groups showed some 7 degree of response during the 6-week follow-up. Group 1 included patients with mild symptoms 8 (initial mean score of 3.8) and a reduction to nearly 0 at the end of the follow-up ("Responders"). 9
Group 4 included patients with initially high negative scores (mean, 13.9) and a progressive 10 reduction to a mean score of 3.2 ("Partial Responders"). Finally, Group 5 included the patients 11
with both the highest negative scores and weakest responses over the investigated period ("Poor 12
Responders"). Only diagnosis had significant effects on the probabilities of following particular 13 trajectories of negative symptoms ( 
Trajectories of BPRS total scores 21
Four trajectories for the BPRS total score were found, which were very similar to four of the five 22 trajectories found for the SAPS-SANS positive dimension (Figure 2) . That is, a group analogous 23 to that of the Slow Partial Responders of the SAPS-SANS positive dimension (Group 4 in Figure  1 1A) was not observed in the BPRS total score. 2
Discussion 3
Our results show a remarkable interindividual variation in the response to treatment in 4 patients with a first episode of psychosis, which replicates and extends previous research. We 5 found different numbers of trajectories across the three analyzed symptomatic dimensions: 5 6 trajectories for the positive dimension, 3 for the disorganized dimension and 5 for the negative 7 dimension. The dimensions changed differentially over time; their changes had associated 8 predictor factors that are discussed below. 9
Trajectories of SAPS-SANS positive dimension 10
Similarly to previous reports that focused on positive symptoms using other scales 11 this study used a different statistical methodology. 12
Differences in conclusions between this and previous studies may also be due to the fact 13 that previous studies used total PANSS or BPRS scores as symptomatology ratings. BPRS and 14 PANSS positive scales included items representing disorganized symptoms, making it difficult to 15 translate results in terms of severity or thresholds and to make comparisons. According to our 16 results, the trajectories of these two dimensions may be quite different and combining symptoms 17 of disorganization with reality distortion may bias the results in trajectory analyses. In contrast 18 with some previous studies, we were not able to find any trajectories that could be identified as 19 With regard to antipsychotic treatment we were not able to find any differences in the 1 response trajectories of the investigated dimensions across the three investigated antipsychotics 2 (haloperidol, risperidone and olanzapine), but we cannot rule out the possibility that including 3 other antipsychotics may contribute to differences. However, the lack of a differential response is 4 consistent with our previous analysis of effectiveness in our sample, which did not show any 5 differences in the positive or negative symptoms across various antipsychotic treatments, 6 (Crespo-Facorro et al., 2006) and with a previous meta-analysis that suggested that the efficacy 7 of atypical antipsychotics is similar to that of haloperidol when controlling for dosage (Geddes et 8 al., 2000) . Similarly, no differences have been found between the response trajectories of 9 risperidone and amisulpride (Levine & Leucht, 2010) . However, previous studies found that 10 "dramatic response" curves were associated with ziprasidone treatment when compared to 11 quetiapine, risperidone, olanzapine and aripiprazole, whereas aripiprazole was associated with 12 "delayed response curves" (Stauffer et al., 2011) . Additionally, a post hoc study based on CATIE 13 study phase 1 showed that patients treated with olanzapine were more likely to belong to the 14 trajectory of responders when compared with patients treated with perphenazine, risperidone, 15 quetiapine and ziprasidone . These results, however, may be mediated, at 16 least in part, by the heterogeneity induced by patients' chronicity, high drop-out rates and follow-17
It is remarkable that the results of this study concerning the SAPS-SANS positive 19 dimension are very similar to results obtained by previous studies, despite the fact that a 20 substantially different statistical modeling approach was used. The modeling approach used in 21 our study essentially consists of two steps (Jones, 2001) . In the first step, the probability 22 distribution of the positive dimension score at the end of a particular week of treatment is 23 assumed to be a mixture of an unknown number of probability distributions. It is also assumed 1 that this unknown number is the same across weeks, and that the means of these distributions are 2 related with the number of weeks under treatment in a way described by a polynomial equation 3
( Table 1 ). The main goal of the first step is to identify this unknown number which, in our 4 context, is the number of "trajectories". In the second step, the effect of predictor factors on the 5 "risk" that a particular dimension score comes from a particular probability distribution is 6 modeled in a way analogous to the way a risk is modeled in multinomial logistic regression, 7
assuming that the effect of a particular predictor is the same across weeks. In fact, if only two 8 probability distributions were identified in the first step, the second step essentially fitted the 9 usual logistic regression model that epidemiologists are accustomed to use. A natural 10 consequence of this approach is that odds ratios can be computed and interpreted in the same 11 way as in logistic regression, as we did in the Results Section. The overall modeling approach, 12 however, does not require that the "risk" of coming from a particular probability distribution (i.e. 13 the risk that a subject follows a particular trajectory) be computed prior to estimating the effects 14 of the predictors on this risk, because the mixture distribution used in the first step and the 15 multinomial regression model of the second step are mathematically coupled during the 16 estimation of predictor effects. 17
On the other hand, previous studies have used latent growth curve modeling, which 18 essentially uses covariance structure models that treat the parameters of the equations that 19 describe the trajectories as random variables governed by continuous probability distributions. In 20 contrast, the approach used in our study assumes that these parameters are fixed, non-random 21 quantities and, as described above, assumes a substantially different mathematical structure for 22 the probability of following a particular trajectory and the way predictor variables are related 1 with this probability. 2 3
Trajectories of SAPS-SANS disorganized dimension 4
Three trajectories were identified in the response of disorganized dimension, which were 5 almost parallel ( Figure 2) . Interestingly, the 66.7% of patients with a Dramatic Response (Group 6
2) had a moderate initial severity of disorganized symptoms and on average responded rapidly 7 and almost completely, suggesting a better response pattern in disorganized symptoms for these 8 patients. Cannabis use was the only investigated factor that was significantly associated with 9
higher severity and poorer response in disorganized symptoms, in accordance with previous 
Trajectories of SAPS-SANS negative dimension 22
Our study identified five response trajectories for the negative dimension, which 1 exhibited substantially different patterns if compared to the other two symptom dimensions. Mild 2
Non-Responders and Moderate Non-Responders together accounted for 55.6% of the sample, 3
including patients who exhibited initial mild to medium severity scores but showed minimal 4 variation during the six-week investigated period, suggesting a persistent severity. The other 5 three groups showed some degree of response. In particular, patients in the Responders trajectory 6 had the mildest initial severity and showed the most complete response. Patients in the Partial 7
Responders trajectory started from a high level of severity, but exhibited a rapid and strong 8 response; however, their response was incomplete at the end of follow-up. Finally, patients in the 9
Poor Responders trajectory exhibited the highest severity, with a mild response both initially and 10 during follow-up. A recent study (Levine & Leucht, 2012) found a predominance of early 11 response during the first two weeks of treatment compared to the following four weeks; 12 however, this study also found a delayed onset response from days 42 to 60, suggesting that a 13 long-term evaluation of negative symptoms is required. This implies that patients of our study 14 other than Responders or Partial Responders may have shown additional changes in their 15 negative symptoms if the follow-up had been extended beyond week 6. 16
Interestingly, previous studies that tried to identify trajectories of response in negative 17 symptoms were not able to find a model for negative symptoms, (Marques et al., 2011) The only factor associated with some trajectories of negative dimension was diagnosis. ). An unexpected negative result is that we did not find an 9 association between DUP and trajectories of the negative dimension. 10
Trajectories of BPRS total scores 11
The four trajectories found for the BPRS total scores were very similar to the four trajectories 12 included chronic patients who may be less responsive to treatment compared to first episode 21 patients. As previously discussed, differences in the number of trajectories and the degree of 22 response between our study and previous studies may be accounted at least in part by the 1 inclusion of different symptomatic domains in symptom assessments. 2
Limitations 3
The present study has several limitations that should be taken into consideration. First, 4
comparability with previous studies is reduced by the fact that responses were evaluated in 5 different symptom dimensions of the SANS-SAPS scales. Our approach may allow a better 6 understanding of the heterogeneity of response and may represent a much improved approach 7 compared to previous studies. Secondly, the follow-up only included short-term responses and 8 response trajectories may be different in the long term. Thirdly, the sample size limits the 9 number of classes identified. Finally, the number of factors analyzed was small and did not 10 include some of the factors investigated in previous studies. The sample size, however, limits the 11 number of variables that can be analyzed. 12
Clinical Implications 13
Our results suggest that different patients follow different patterns of response and that the 14 different symptomatic dimensions obey different trajectories over time. In the case of positive 15 symptoms, such as reality distortion, a substantial reduction of symptoms would be expected in a 16 great majority of patients. Even a third of the patients may remit during a short trial of six week 17 of treatment. However, given that patients start from very different baseline severity scores and 18 the response change is quite heterogeneous among groups, response rates at the initial two weeks 19 of treatment may not be good predictors of the response at later weeks; for instance, Responder 20 patients (Group 1) could be considered subjects with a low rate of response at week 1 but 21 remitters at week 6. These trajectories may be modulated at least in part by modifiable factors 22 such as cannabis use and longer DUPs and, therefore, our results may have preventive and 23 therapeutic implications in clinical settings. In the disorganized dimension, our results suggest 1 that most patients would be responsive but those subjects with more severe symptoms have a 2 lower probability of achieving a complete response; and this severity may also be related to the 3 use of cannabis. With regard to negative symptoms, the heterogeneity of responses seems to be 4 considerably higher and the rate of response appears to be lower in the short-term, however a 5 number of patients still appears to be responsive. Only factors related to the illness seem to be 6 related to the response to antipsychotic treatment when negative symptoms are considered. 7
Given the nature of these symptoms and the mechanisms involved in their modification, a short -8 term pharmacological treatment may not be sufficient to observe a complete effect on negative 9 symptoms. 10
Conclusions 11
The current naturalistic clinical trial investigated a representative sample of patients with 12 a first episode of psychosis, and focused on the analysis of the changes of 3 symptom dimensions 13 in response to antipsychotic treatment over the course of 6 weeks. Our results illustrate different 14 patterns of short-term changes and trajectories in the psychotic reality distortion, disorganization 15 and negative dimensions. Whereas our results on the trajectories of the positive dimension are 16 comparable with results from previous studies that found a five-trajectory model, the 17 disorganized and particularly the negative dimensions showed marked differences with previous 18 reports, probably caused by differences in study designs and investigated populations. A number 19 of predictor factors affected response heterogeneity: longer DUPs were associated with poorer-20 outcome trajectories in the positive dimension, cannabis use was related to trajectories of worse 21 outcome in the positive and disorganized dimensions, and negative-dimension trajectories with 22 high overall symptom severity were associated with a diagnosis of schizophrenia. 23
